eFFECTOR Therapeutics Q2 EPS $(0.17) Beats $(0.20) Estimate
Portfolio Pulse from Benzinga Newsdesk
eFFECTOR Therapeutics reported Q2 losses of $(0.17) per share, beating the analyst consensus estimate of $(0.20) by 15 percent. This is unchanged from the same period last year.
August 08, 2023 | 9:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
eFFECTOR Therapeutics' Q2 earnings per share beat analyst estimates by 15%, which could positively impact the stock in the short term.
eFFECTOR Therapeutics reported better than expected Q2 earnings per share, which is a key indicator of a company's profitability. This could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100